GMP compliance in pharmaceutical manufacturing means following a set of legally enforced quality standards that ensure medicines are consistently produced, controlled, and tested to the quality levels required for their intended use. These standards govern everything from facility design and equipment qualification to personnel training and batch release. The sections below unpack the most common questions manufacturers ask about GMP requirements, audits, documentation, and certification.
What are the core principles behind GMP requirements?
GMP requirements are built on the principle that quality cannot be tested into a finished product — it must be built into every step of the manufacturing process. This means that procedures, people, premises, and equipment must all meet defined standards before a single batch is produced, not just when a regulator comes to inspect.
The core principles that underpin GMP compliance include:
- Documented procedures: Every critical operation must be written down, approved, and followed consistently
- Qualified personnel: Staff must be trained for their roles, and that training must be recorded
- Validated processes: Manufacturing processes must be proven to deliver consistent results before routine production begins
- Controlled environments: Premises and equipment must be designed, maintained, and qualified to prevent contamination and mix-ups
- Traceability: Every batch must be traceable from raw material sourcing through to distribution
- Continuous improvement: Deviations, complaints, and audits must feed back into the quality system to prevent recurrence
These principles apply whether a company manufactures small molecules, biologics, or advanced therapy medicinal products. The specific technical requirements vary by product type and region, but the underlying logic remains the same: build quality in, document everything, and continuously verify that the system is working. If you would like to learn more about how we support manufacturers across these areas, visit our services overview.
Which regulatory bodies set GMP standards for pharmaceuticals?
GMP standards for pharmaceuticals are set by national and regional regulatory authorities, with the most influential being the European Medicines Agency (EMA) and national competent authorities in the EU, the U.S. Food and Drug Administration (FDA), and the World Health Organization (WHO) for international markets.
In the European Union, GMP requirements are laid out in the EU GMP Guidelines (EudraLex Volume 4), which are legally binding for manufacturers placing medicinal products on the EU market. The guidelines are divided into Parts I, II, and III, covering human medicines, active substances, and GMP-related documents respectively, with additional Annexes addressing specific product types such as sterile products, biologicals, and radiopharmaceuticals.
In the United States, the FDA enforces Current Good Manufacturing Practice (cGMP) regulations under 21 CFR Parts 210 and 211 for finished pharmaceuticals, and 21 CFR Part 600 for biologics. The FDA’s cGMP framework emphasizes flexibility, expecting manufacturers to use up-to-date technologies and systems rather than following a rigid prescriptive checklist.
The ICH (International Council for Harmonisation) plays an important bridging role, producing harmonized guidelines such as ICH Q7 for active pharmaceutical ingredients and ICH Q10 for pharmaceutical quality systems that are adopted across multiple jurisdictions. For manufacturers exporting globally, understanding which authority governs each target market is a foundational step in building a GMP compliance strategy.
How does a GMP audit actually work?
A GMP audit is a systematic, documented examination of a pharmaceutical manufacturer’s facilities, processes, and quality systems to verify that GMP requirements are being met. Audits can be conducted by regulatory authorities (inspections), by customers (supplier audits), or internally by the manufacturer’s own quality team.
Regulatory GMP inspections
Regulatory inspections are carried out by competent authorities such as the national medicines agencies within the EU or the FDA. Inspectors review batch records, standard operating procedures, deviation logs, validation reports, and training records. They observe manufacturing operations, interview staff, and assess the physical premises. At the end of an inspection, findings are categorised by severity, typically as critical, major, or minor observations. Critical findings can result in the suspension of a manufacturing licence.
Internal and supplier audits
Internal audits serve as a self-assessment tool, helping manufacturers identify gaps before a regulatory inspection. Supplier audits are conducted when qualifying a contract manufacturer, an API supplier, or a testing laboratory. Both types follow a similar format: a pre-audit document review, an on-site visit with interviews and a facility walkthrough, and a written report with corrective action requirements. A well-run internal audit programme is one of the strongest indicators of a mature quality culture.
What documentation is required for GMP compliance?
GMP compliance requires a comprehensive documentation system covering the design, operation, and control of every aspect of manufacturing. The core documents include master batch records, standard operating procedures (SOPs), specifications, validation protocols and reports, deviation and change control records, and training logs.
The documentation hierarchy typically looks like this:
- Quality manual and quality policy: Top-level documents defining the quality management system
- Standard operating procedures: Step-by-step instructions for all critical operations
- Specifications and test methods: Defined acceptance criteria for raw materials, intermediates, and finished products
- Batch manufacturing and packaging records: Completed records proving each batch was made according to its master record
- Validation and qualification reports: Evidence that equipment, processes, and analytical methods perform as intended
- Deviation, OOS, and CAPA records: Documentation of problems identified and corrective actions taken
Data integrity is a critical theme running through all GMP documentation. Records must be attributable, legible, contemporaneous, original, and accurate — a principle sometimes summarised as ALCOA. Regulatory agencies have increased scrutiny of data integrity in recent years, and deficiencies in this area are among the most common reasons for warning letters and import alerts.
What are the most common GMP compliance failures?
The most common GMP compliance failures relate to inadequate documentation, poor change control, insufficient process validation, and weak deviation management. These failures appear repeatedly in regulatory inspection reports across all regions and product types.
Specific recurring issues include:
- Data integrity gaps: Incomplete, altered, or backdated records that undermine trust in the entire quality system
- Uncontrolled changes: Modifications to processes, equipment, or suppliers made without formal change control assessment
- Inadequate out-of-specification (OOS) investigations: Failing to fully investigate and resolve test failures before releasing or rejecting a batch
- Training deficiencies: Personnel performing tasks without documented, up-to-date training records
- Contamination control failures: Gaps in environmental monitoring, cleaning validation, or gowning procedures, particularly in sterile manufacturing
- Supplier qualification weaknesses: Using contract manufacturers or API suppliers without adequate qualification and ongoing oversight
Many of these failures share a common root cause: quality systems that exist on paper but are not embedded in day-to-day practice. A procedure that nobody follows is not a control — it is a liability during an inspection. To find out more about the expertise behind our compliance support, see our company background.
When does a pharmaceutical manufacturer need a GMP certificate?
A pharmaceutical manufacturer needs a GMP certificate when applying for a manufacturing authorisation, when supplying medicinal products to regulated markets, or when a marketing authorisation application references the manufacturing site. In the EU, a GMP certificate is issued by a national competent authority following a satisfactory inspection and is required for any site involved in manufacturing, importing, or testing medicinal products.
GMP certificates are also frequently requested outside of regulatory submissions. Contract manufacturers often need to provide a current GMP certificate to prospective clients as part of supplier qualification. Marketing authorisation holders may need to demonstrate the GMP status of their manufacturing sites when applying for approval in new markets.
In the EU, GMP certificates are publicly available through the EudraGMDP database, which allows anyone to verify the GMP status of a manufacturing site. Certificates have a defined validity period and must be renewed following re-inspection. A site that has received critical findings during an inspection may have its certificate suspended or withdrawn, which directly affects the ability to supply product to the market.
How Starodub supports your GMP compliance journey
Navigating GMP requirements across multiple markets is complex, and the regulatory landscape continues to evolve. At Starodub, we work alongside biopharmaceutical and medical device companies to make that process manageable and efficient. Our team brings hands-on experience across the full range of GMP-related activities, including:
- Preparation and review of GMP documentation, including SOPs, validation protocols, and batch record templates
- Gap assessments ahead of regulatory inspections, identifying risks before an inspector does
- Support with deviation management, CAPA programmes, and change control systems
- Guidance on EU GMP requirements for medicinal products, including biologics, ATMPs, and combination products
- Assistance with supplier qualification and audit support for contract manufacturers and API suppliers
- Quality system improvements through our Quality, Compliance and Operational Improvements division, led by Lean Six Sigma Master Black Belts with over 25 years of pharmaceutical industry experience
Whether you are preparing for your first GMP inspection, responding to regulatory observations, or building a quality system from the ground up, we provide clear, practical support backed by deep regulatory expertise. Get in touch with the Starodub team today by visiting our contacts page to discuss how we can help your organisation achieve and maintain GMP compliance.
Related Articles
- How do you integrate quality by design into regulatory strategy?
- What is the role of regulatory science in strategic planning?
- How long does it take to get approved for EMA?
- What is the average time to approve a drug?
- How do you navigate medical device regulations for combination products?
This content was generated with the help of AI and it may contain mistakes
